) -- Adam Feuerstein's take on the biotech week that ended Nov. 12, 2010:
The week's best-performing stocks in the sector:
Is it any coincidence that Aastrom filed a $75 million mixed shelf registration Friday?
Human Genome Sciences
The week's worst-performing stocks:
( EPCT) (-28%),
( ANPI) (-21%) and
sold 11.5 million shares at $8, raising $86 million to fund commercial launch of Ofirmev, a hospital-based intravenous form of acetameniphan.
> > Bull or Bear? Vote in Our Poll
received FDA clearance to start phase II study of Multistem stem cell therapy for inflammatory bowel disease.
Research abstracts for
American Society of Hematology
annual meeting were
priced 7.37 million stock units (stock and warrants) at $2.85 a unit, raising $20 million.
to begin human clinical trials of antibiotic PMX-30063.
filed for FDA approval of an expansion to its Provenge manufacturing plant in New Jersey, while the Centers for Medicare and Medicaid (CMS) released the technical assessment of Dendreon's Provenge ahead of next week's National Coverage Determination meeting.
( MITI) sold 9.9 million shares at $7.30, raising $72 million.
, Arena Pharmaceuticals,
, and Osiris Therapeutics.
facing Human Genome Sciences, Dendreon and
Lawyer Indicted for Obstructing the FDA
(via invivo blog)
--Written by Adam Feuerstein in Boston.
>To contact the writer of this article, click here:
>To follow the writer on Twitter, go to
>To submit a news tip, send an email to:
Adam Feuerstein writes regularly for TheStreet.com. In keeping with TSC's editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet.com. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;
to send him an email.